Florida Cancer Innovation Fund FY 2026-27

Florida has approximately $70 million available through the FY 2026-27 Florida Cancer Innovation Fund for high-impact cancer innovation, clinical and translational work, implementation, technology, screening, nutrition-based prevention and related initiatives. Eligible Florida-based organizations may request up to $2 million; the first rolling application period closes September 25, 2026 at 11:59 PM ET.

FundingApproximately $70 million available statewide; applicants may request up to $2 million.

DeadlinePeriod 1: September 25, 2026 at 11:59 PM ET. Period 2: November 6, 2026 at 11:59 PM ET. The FOA describes Period 3 as November 7-December 18, 2026 but contains an internal submission-deadline inconsistency; applicants should confirm the final Period 3 deadline with Florida DOH.

Last verifiedAugust 29, 2026

Required next actionReview the controlling FY 2026-27 Funding Opportunity Announcement and confirm the applicant meets Florida-based institutional eligibility; select an eligible high-impact cancer innovation, clinical, translational, implementation, screening, nutrition or technology project; confirm the project can be completed within the required 12-month period; prepare the application in the Florida Cancer Connect Collaborative portal and submit for the September 25 first-period deadline or a later rolling period if appropriate.

Broad Eligibility

Florida-based licensed or certified healthcare providers, facilities and entities meeting at least one qualifying criterion in the FOA, including certain rural or underserved hospitals, rural hospitals, Critical Access Hospitals, pediatric specialty hospitals, oncology clinics or treatment facilities, low- or no-cost cancer screening providers, accredited cancer programs, biomedical research organizations and institutions training cancer-screening, diagnostic or treatment practitioners.

Atlas Analysis

One of Florida's highest-value currently actionable healthcare funding opportunities. The fund strongly favors implementation-ready, high-impact cancer innovation with direct patient or system benefit, including clinical and translational approaches, technology, screening, nutrition-based prevention and generic-drug repurposing. Rural, underserved and nonmetropolitan impact is strategically important. Atlas uses the official FY 2026-27 FOA as the controlling source and flags its internal Period 3 deadline inconsistency rather than guessing.

Source verificationOfficial government source · www.floridahealth.govAtlas last verified this record August 29, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗